Skip to main content
PACB logo

PACB · Pacific Biosciences Of California, Inc.

Track PACB — free
$1.86 -0.11 (-5.36%)
Market Cap
$613.34M
Shares
312.93M
Volume · Nov 16 4.81M Avg daily vol (3M) 12.42M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.96 Open$1.99 Day$1.84–2.00 52W close$1.11–2.90 Avg vol 30d14.5M Short int53.7M · 17.2% of shares · 4.1d Short vol67% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 11, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 10
Current report 8-K
$100,000,000 At-the-Market Offering Agreement

Pacific Biosciences of California, Inc. entered a sales agreement with Allen & Company LLC for an at-the-market offering of common stock with aggregate sales proceeds of up to $100,000,000. Allen will receive compensation of up to 3.0% of gross proceeds.

Entered into a material agreement Read from the first part of this long document
2 source passages
On November 10, 2026, Pacific Biosciences of California, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Allen & Company LLC (“Allen”) to sell shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having aggregate sales proceeds of up to $100,000,000 (the “Shares”), from time to time, through an “at-the-market” equity offering program under which Allen will act as sales agent. The Sales Agreement provides that Allen will be entitled to compensation for its services in an amount equal to up to 3.0% of the aggregate gross proceeds from the Shares sold through Allen under the Sales Agreement. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PacBio revenue rises 6%, but gross profit falls 15%

PacBio reported third-quarter 2026 revenue growth of 6% and a 15% gross profit decline. Cash, cash equivalents and investments were $199.4 million at September 30, 2026, down 29% from December 31, 2025.

Revenue $40.56M ▲ 5.5% Net loss $37.85M Diluted EPS -$0.12
Read from the MD&A section
4 source passages
About PacBio Total revenue increased $2.1 million, or 6%, for the third quarter of 2026 compared with the same quarter of 2025. Gross profit decreased $2.4 million, or 15%, during the third quarter of 2026 compared to the same period of 2025. Cash, cash equivalents, and investments were $199.4 million at September 30, 2026, which represents a 29% decrease compared to the balance at December 31, 2025. Open the document at this passage
Nov 4
Earnings call
Revenue grows 6% as gross margin declines

PACBIO reported third quarter 2026 revenue of $40.6 million, up 6% year over year, and narrowed 2026 revenue guidance to $155 to $160 million; non-GAAP gross margin fell to 36% from 42%.

4 source passages
Good afternoon, and welcome to PACBIO's third quarter 2026 earnings conference call. We recorded total revenue of $40.6 million in the third quarter of 2026, compared to $38.4 million in the third quarter of 2025, reflecting 6% growth year over year. We are narrowing our full-year revenue guidance to $155 to $160 million. Third quarter non-GAAP gross profit of $14.6 million represented a non-GAAP gross margin of 36%. Compared to a non-GAAP gross profit of $16.2 million or a gross margin of 42% in the third quarter of 2025. Open the document at this passage
Nov 4
Current report 8-K Events of Nov 3
Jim Gibson steps down; third-quarter revenue reaches $40.6 million

Pacific Biosciences of California, Inc. reported $40.6 million in third-quarter revenue for the quarter ended September 30, 2026. Jim Gibson stepped down as CFO, Mark Van Oene became interim CFO, and 2026 revenue guidance is $155 million to $160 million.

Financial results, Director or officer change, or executive pay
4 source passages
Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its third fiscal quarter ended September 30, 2026. Delivered total revenue of $40.6 million, reflecting continued instrument and consumables demand Jim Gibson has stepped down as Chief Financial Officer (CFO). Mark Van Oene has been appointed interim CFO and Bill Meyer has been appointed Chief Accounting Officer (CAO) as PacBio engages in a search for a new CFO PacBio now expects revenue for the full year 2026 to be in the range of $155 million to $160 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$161.39M
Trailing 12 months
Net income (TTM)
−$131.23M
Trailing 12 months
Revenue growth YoY
+5.5%
Year over year
Operating margin
-81.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$443.64M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.5%
Year over year · more shares
Price change (1Y)
+20.2%
Trailing year
Short interest
17.2%
Latest settlement · 4.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Q3 revenue grew 6% year over year as SPRQ-Nx adoption expanded, clinical consumables grew more than 20%, and new clinical and AI collaborations broadened PacBio’s opportunity. The outlook includes lower operating expenses and 2028 cash-flow break-even, but consumables pull-through and gross margin declined, funding constraints persisted, cash fell, and PacBio continued to report a substantial net loss.

Bullish
  • + Q3 revenue grew 6% year over year to $40.6 million, with instrument revenue increasing 16% to $13.2 million.
  • + SPRQ-Nx adoption reached over half of Revio consumables revenue, with two-thirds of the installed base upgrading by quarter-end.
  • + Clinical consumables revenue was growing more than 20% year over year and represented more than 20% of overall business.
  • + The GeneDx partnership is expected to deepen PacBio's role in rare disease and support its clinical growth strategy.
  • + The multi-year Verily Health collaboration is expected to bring HiFi long-read data to a research community of more than 20,000 users.
  • + Restructuring savings are expected to reduce 2026 operating expenses to $203–$207 million, with cash-flow break-even expected in 2028.
Bearish
  • − Consumables revenue declined year over year to $20.8 million from $21.3 million as sequencing activity grew faster than purchases.
  • − Annualized Revio pull-through was ~$204,000 versus ~$236,000 in the prior-year quarter.
  • − Non-GAAP gross margin declined to 36% from 42% because of higher memory costs and Vega manufacturing-transition costs.
  • − Americas instrument revenue declined approximately 24% as academic and government funding uncertainty constrained capital purchasing.
  • − Cash, cash equivalents, and investments declined to approximately $199.4 million from $279.5 million at December 31, 2025.
  • − PacBio reported a $32.8 million non-GAAP net loss, or 11 cents per share.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +22%
above
Price vs 50-day avg −2%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +56%
trailing
YTD return +5%
this year
Relative strength +55%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
178 of 223 funds reported for Sep 30 · net +4.5M sh shares · +13 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.15% of shares out · ▲ +14.4% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
223 holders — mid 3-yr range
Squeeze score 79
high risk · 0–100
Fundamentals
Weak
Revenue growth +3%
Y/Y
Gross margin 49%
expanding
EPS growth −14%
Y/Y
Free cash flow $-113.9M
Balance sheet $581.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 94%
annualized · 1-yr
Max drawdown −58%
past year
ATR 14.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 4
Latest guidance · from the Earnings Call filed Aug 5, 2026
for the full year
Revio pull-through per system $200,000 – $225,000
2026
Revenue Lowered $155M – $165M
May 7, 2026 $165M – $175M changed to Aug 5, 2026 $155M – $165M
prior FY $160.01M midpoint −0.0% Y/Y
Non-GAAP gross margin Non-GAAP 35% – 37%
Non-GAAP operating expenses Non-GAAP Lowered $215M – $220M
May 7, 2026 $220M – $225M changed to Aug 5, 2026 $215M – $220M
end of 2026
Cash, cash equivalents, and investments (year-end balance) $175M – $185M
next year (2027)
Compensation-related expense reduction from restructuring $15M – $20M
annual
Additional annual savings past high-throughput platform developm $15M – $20M
this year
Revenue $155M – $165M
Previous outlook earlier release · from the Earnings Call filed Nov 5, 2025

Still-open targets the latest release did not restate under the same label.

Cost of human genome sequencing · at scale up to $300
Revenue · Q4 10%
Prior guidance period ended · from the 8-K filed Aug 5, 2026
Aggregate pre-tax charges · third quarter of 2026 $2M
Guided vs delivered · last 4 settled
Revenue full year of 2025
guided $155M – $160M
$160.01M Beat +1.6%
2024 revenue 2024
guided $170M – $200M
$154.01M Miss −16.7%
Revenue 2022
guided $138M – $145M
$128.3M Miss −9.3%
Annual revenue full year 2021
guided $128M – $132M
$130.51M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+22% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
178 of 223 funds reported for Sep 30 · net +4.5M sh shares · +13 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.15% of shares out · ▲ +14.4% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
223 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 47% Range high $3
vs 200-day avg +22% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Annualized Revio pull-through per system $202,000 Q2 2026 —
Revio system placements 20 Q2 2026 —
Vega system placements 26 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PACB
Pacific Biosciences Of California, Inc.
this stock
$613.34M +4.8% +3.0% — 17.2%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
205
% held
62.5%
Reported
178 of 223
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
144
View
Short & Settlement
Short Interest Rising
Shares short
53.7M
Days to cover
4.1d
Change
+6.7M sh
View
Short Volume
Short vol %
67%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
18.3K
Value
$51.9K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
45.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$78.6M
Net income (FY)
$-546.4M
EPS diluted
$-1.82
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 10, 2026
This year
22

Pacific Biosciences of California, Inc. entered a sales agreement with Allen & Company LLC for an at-the-market offering of common stock with aggregate sales proceeds of up to $100,000,000. Allen will receive compensation of up to 3.0% of gross proceeds.

View
Proposed Sales
Value
$1.9M
Shares
661.8K
Filed
Oct 6, 2026
View
Exempt Offerings
Offering
$84.8M
Filed
Oct 19, 2023
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 17, 2026
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
PacBio to Report Third Quarter 20…
Published
Oct 14, 2026
Upcoming events
5
View

Performance

5D 20D 120D MTD YTD
PACB -13.1% +13.3% +55.6% -24.8% +4.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -15.7% +14.5% +55.1% -24.6% -5.8%
Key facts CIK 1299130 CUSIP 69404D108 13F (30d) 158 filings 139 filers Visit website Investor relations